Childhood Acute Lymphoblastic Leukemia Clinical Trial
Official title:
The Effect of Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae: A Randomized Controlled Trial
Survivors of childhood cancer are at risk for developing neurocognitive sequelae. Multiple meta-analyses demonstrate significant deficits in overall intellectual abilities, academic functioning and specific cognitive skills among survivors of childhood cancer treated with intrathecal chemotherapy only and/or cranial irradiation. Preventing neurocognitive deficits is therefore of great importance. Unfortunately, intervention studies for this group of survivors are scarce. The main aim of this randomized controlled trial is to determine the efficacy of Goal Management Training (GMT) as a group-based treatment program for 60 adult survivors of childhood leukemia, and non Hodgkins lymphoma, diagnosed between 1980 and 2017 at an age below 18, with attention and executive function deficits. The participants will be randomized to one treatment group (GMT), and one waitlist condition followed by one active control intervention, the "Brain health workshop" (BHW), which has a psycho-educative approach. The follow-up time from diagnosis will be ≥5 years and the age at survey 18-40 years. The study will expand the knowledge base on treatment factors important in improving cognitive function. Results from this study can be implemented in rehabilitation for the young adult survivors of childhood leukemia, and non Hodgkins lymphoma, which will be of importance for their future educational and work-related functioning.
Effect of the GMT/waitlist conditions will be assessed through self-reported and objective measures of neuropsychological function, quality of life and health measurements. To avoid extra training effects of neuropsychological testing on participants allocated to waitlist/BHW, assessment following BHW (approximately one-year post T1) will consist of self-report measures only. Patients in all groups will be reassessed within 14 days post intervention (T2), and at 6 months post intervention (T3). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01990807 -
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
|
Phase 4 | |
Completed |
NCT00898079 -
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
|
||
Recruiting |
NCT03390387 -
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
|
N/A | |
Withdrawn |
NCT01492569 -
Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting
|
N/A | |
Recruiting |
NCT05452668 -
Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients
|
N/A | |
Recruiting |
NCT05729178 -
Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias
|
||
Recruiting |
NCT03981510 -
Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation
|
N/A | |
Completed |
NCT01150669 -
Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
|
N/A | |
Active, not recruiting |
NCT01953770 -
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008
|
N/A | |
Completed |
NCT00674193 -
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
|
N/A | |
Completed |
NCT00537030 -
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
|
N/A | |
Recruiting |
NCT04723342 -
Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot
|
N/A | |
Completed |
NCT01251575 -
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT04626765 -
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
|
Early Phase 1 |